Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.
Cheung, Stephane; Hamuro, Yukinobu; Mahlich, Jörg; Nakayama, Masahiko; Tsubota, Akiko.
; 13(4): e0195789, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29694373
Integrative clinical genomics of advanced prostate cancer.
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.
Genomic hallmarks of localized, non-indolent prostate cancer.
The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments.
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales.
No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer.
New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.